Gilead Sciences (GILD)

• Market cap: $150B
• 1 day: -0.02%
• 5 days: -2.58%
• 1 month: 2.57%
• 3 months: 4.58%
• 6 months: 7.25%
• Year to date: 31.9%
• 1 year: 33.78%
• 5 years: 98.12%
• 10 years: 17.06%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Employees: 17,600